Which of the following is a biosimilar to filgrastim (Neupogen)?

Prepare for the CPJE Law Test. Explore flashcards and multiple choice questions with detailed explanations. Ace your exam with comprehensive prep!

Multiple Choice

Which of the following is a biosimilar to filgrastim (Neupogen)?

Biosimilars are highly similar to an approved biologic, with no clinically meaningful differences in safety, purity, or potency. Filgrastim is a recombinant G-CSF used to treat neutropenia, so a true biosimilar would be another product proven to be highly similar to filgrastim in structure, function, and clinical effect. Filgrastim-sndz, marketed as Zarxio, is the biosimilar to the original filgrastim product (Neupogen) and has been shown to have no meaningful differences in safety or efficacy. Filgrastim (Neupogen) is the reference product, not a biosimilar. Pegfilgrastim (Neulasta) is a pegylated, longer-acting form of G-CSF and is not a biosimilar to filgrastim. Sargramostim (Leukine) is a different growth factor (GM-CSF), not a G-CSF, so it is not a biosimilar to filgrastim.

Biosimilars are highly similar to an approved biologic, with no clinically meaningful differences in safety, purity, or potency. Filgrastim is a recombinant G-CSF used to treat neutropenia, so a true biosimilar would be another product proven to be highly similar to filgrastim in structure, function, and clinical effect. Filgrastim-sndz, marketed as Zarxio, is the biosimilar to the original filgrastim product (Neupogen) and has been shown to have no meaningful differences in safety or efficacy. Filgrastim (Neupogen) is the reference product, not a biosimilar. Pegfilgrastim (Neulasta) is a pegylated, longer-acting form of G-CSF and is not a biosimilar to filgrastim. Sargramostim (Leukine) is a different growth factor (GM-CSF), not a G-CSF, so it is not a biosimilar to filgrastim.

More practice questions